NRx Pharmaceuticals' Interim CEO and other Leaders to Present at 21st Annual Needham Virtual Healthcare Conference
NRx Pharmaceuticals (Nasdaq: NRXP) will present a corporate update at the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 4:30 PM ET. Interim CEO Robert Besthof and other executives will provide insights on the company's progress and future plans. The presentation will be accessible to investors, media, and the public via a live webcast. NRx specializes in biopharmaceuticals, with its lead products in Phase III trials, including ZYESAMI®, targeted for COVID-19, and NRX-101 for severe bipolar depression.
- None.
- None.
Company to Present Corporate Update During Investor Webcast, April 14, 2022, at 4:30pm ET
RADNOR, Pa., April 8, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company, today announced its interim Chief Executive Officer, Robert Besthof, and other executive leaders will be presenting updates to the company's business at the 21st Annual Needham Virtual Healthcare Conference.
Webcast Presentation Details:
Investors, media, and the public are invited to listen to the live webcast.
Date: Thursday, April 14, 2022
Time: 4:30 p.m., Eastern Time
Link to Presentation:
https://sandbox-m-nrx.pantheonsite.io/21st-annual-needham-virtual-healthcare-conference
(A replay will be available on the NRx Pharmaceuticals website following the presentation at www.nrxpharma.com).
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company") draws upon decades of collective, scientific, and drug-development experience to bring improved health to patients. NRx has two products in Phase III. Its investigational product, ZYESAMI® (aviptadil) for patients with COVID-19, has been granted Fast Track designation by the US Food and Drug Administration (FDA) and is in a Phase III trial for Critical COVID-19 patients which is sponsored and managed by the US National Institutes of Health. The FDA has additionally granted Breakthrough Therapy designation, a Special Protocol Agreement, and a Biomarker Letter of Support for NRX-101, an investigational medicine for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB) after initial stabilization with ketamine or other effective therapy.
NRx Pharmaceuticals is led by executives and board members who have held senior roles at Lilly, Pfizer, GSK and the US FDA. NRx Pharmaceuticals was co-founded by Prof Jonathan Javitt, MD, MPH, who has held leadership roles in various biotechnology startup companies and been appointed to advisory roles in four U.S. Presidential Administrations. The NRx Pharmaceuticals' board includes Dr. Sherry Glied, former U.S. Assistant Secretary for Health (ASPE), Daniel E. Troy, JD, former Chief Counsel of the U.S. FDA, Chaim Hurvitz, former director of Teva and President of the Teva International Group, and General H.R. McMaster, Ph.D. (US Army, Ret.), the 26th United States National Security Advisor.
Cautionary Note Regarding Forward-Looking Statements
This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company's strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company's management.
The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.
CORPORATE CONTACT | INVESTOR RELATIONS | |
Molly Cogan | Eric Goldstein | |
Senior Director, Global Communications | LifeSci Advisors | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-interim-ceo-and-other-leaders-to-present-at-21st-annual-needham-virtual-healthcare-conference-301520850.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
When will NRx Pharmaceuticals present its corporate update?
Who is the interim CEO of NRx Pharmaceuticals?
Where can I watch the NRx Pharmaceuticals webcast?
What products are in development by NRx Pharmaceuticals?
What designations have NRx Pharmaceuticals received for its investigational products?
